MBA MBA - GB Sciences Chief Board

All Insiders . USA . 
Stock . GB Sciences . Stakeholders . Insider . MBA MBA
GBLX Stock  USD 0.0005  0.0001  25.00%   

Insider

MBA MBA is Chief Board of GB Sciences
Age 53
Phone866 721 0297
Webhttps://www.gbsciences.com

GB Sciences Management Efficiency

The company has return on total asset (ROA) of (0.2082) % which means that it has lost $0.2082 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (50.9796) %, meaning that it created substantial loss on money invested by shareholders. GB Sciences' management efficiency ratios could be used to measure how well GB Sciences manages its routine affairs as well as how well it operates its assets and liabilities.
GB Sciences currently holds 397.31 K in liabilities with Debt to Equity (D/E) ratio of 1.07, which is about average as compared to similar companies. GB Sciences has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist GB Sciences until it has trouble settling it off, either with new capital or with free cash flow. So, GB Sciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like GB Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for GBLX to invest in growth at high rates of return. When we think about GB Sciences' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Ron HebertCovalon Technologies
N/A
Hamed AbbasianCovalon Technologies
N/A
Jason GorelCovalon Technologies
N/A
Christina BBAAntibe Therapeutics
N/A
Adi ZuloffShaniScisparc
56
Ana StegicAntibe Therapeutics
N/A
Dr MBACellectis SA
46
MBA MScAntibe Therapeutics
65
Gerry ArambulaCovalon Technologies
N/A
Valerie CrosCellectis SA
N/A
Simon SmithCovalon Technologies
N/A
Pascalyne WilsonCellectis SA
N/A
Kyung NamWortmanCellectis SA
53
Jean EpinatCellectis SA
N/A
Mark DoolittleCovalon Technologies
N/A
MSc MScCellectis SA
54
MEng CFAAntibe Therapeutics
N/A
Oz CPAScisparc
38
Philip SternAntibe Therapeutics
N/A
LLB JDAntibe Therapeutics
65
Elaine ZhangCovalon Technologies
N/A
GB Sciences, Inc. engages in the research and development of plant-based medicines in North America and Europe. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada. Growblox Sciences operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 3 people. GB Sciences [GBLX] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC).

Management Performance

Return On Equity-50.98
Return On Asset-0.21

GB Sciences Leadership Team

Elected by the shareholders, the GB Sciences' board of directors comprises two types of representatives: GB Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GBLX. The board's role is to monitor GB Sciences' management team and ensure that shareholders' interests are well served. GB Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GB Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Krin Kuethe, VP Cultivation
John Poss, President, CFO and COO
Gary Esq, Securities Sec
Zach Swarts, Chief CFO
MBA MBA, Chief Board

GBLX Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is GB Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-50.98
Return On Asset-0.21
Current Valuation10.19 M
Shares Outstanding379.21 M
Shares Owned By Insiders13.08 %
Price To Earning4.04 X
Price To Book1.08 X
Price To Sales1.91 X
Gross Profit(881.46 K)
EBITDA398.73 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
CRMSalesforce
CCitigroup
GMGeneral Motors

Additional Tools for GBLX Pink Sheet Analysis

When running GB Sciences' price analysis, check to measure GB Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GB Sciences is operating at the current time. Most of GB Sciences' value examination focuses on studying past and present price action to predict the probability of GB Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GB Sciences' price. Additionally, you may evaluate how the addition of GB Sciences to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY